Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q3 2026, worth $682.2K in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $5.74M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +3 vs. previous quarter
- 23
- 13F valueReported value at the end of Q3 2026
- $682.2K
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$26.3M
- No comparable prior period
- Free cash flow, FY2025
- -$26.8M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 241.2K
- Shares sold short
- Change
- −71.8K
- −22.9% vs. previous
- Days to cover
- 1.88
- At average daily volume
Superinvestors holding TPST, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding TPST at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Tempest Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 (view filing) | Mar 24 | 91 daysLate | Angel MatthewCEO and President | PPurchase | +231.5K | $2.16 | +$500.0K | New position231.5K after | Duplicate filing |
| Jun 23, 2026 (view filing) | Mar 24 | 91 daysLate | Angel MatthewCEO and President | PPurchase | +463.0K | – | – | –231.5K after | Derivative2 lots |
| Mar 25, 2026 (view filing) | Mar 24 | 1 day | Angel MatthewCEO and President | PPurchase | +231.5K | $2.16 | +$500.0K | New position231.5K after | |
| Aug 12, 2024 (view filing)8:33 PM ET | Aug 8-12 | 4 days | Versant Ventures IV, LLC and 8 others10% Owner | SSale | −788.0K | $1.23 | −$967.0K | −79.0%209.9K after | 2 lots |
| Jul 8, 2024 (view filing) | Jul 3 | 5 days | Brady Stephen RPresident and CEO | PPurchase | +35.0K | $2.11 | +$73.8K | +307.7%46.4K after | |
| Jul 3, 2024 (view filing) | Jul 2 | 1 day | Whiting SamuelChief Medical Officer | PPurchase | +4.67K | $2.13 | +$9.95K | +95.3%9.57K after | |
| Jul 2, 2024 (view filing) | Jun 28 | 4 days | Trojanowski JustinCorporate Controller | PPurchase | +7.50K | $2.16 | +$16.2K | +51.1%22.2K after | |
| May 3, 2022 (view filing) | Apr 29 | 4 days | Woiwode ThomasDirector, 10% Owner | PPurchase | +2.12M | $2.36 | +$5.00M | New position2.12M after | |
| Jan 11, 2022 (view filing) | Jan 7 | 4 days | Dubensky Thomas W.President | PPurchase | +2.00K | $4.78 | +$9.56K | +1.8%113.3K after | |
| Jan 10, 2022 (view filing) | Jan 6 | 4 days | Whiting SamuelChief Medical Officer | PPurchase | +1.70K | $4.80 | +$8.16K | +845.8%1.90K after |
Top 10 13F holders, Q3 2026
See all 23 holdersThe largest institutional positions in Tempest Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Versant Venture Management, LLC | 269,772 | $225.1K | 0.21% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 233,888 | $195.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 74,076 | $61.8K | 0.00% | −12,549−14.5% | Reduced |
| Vanguard Fiduciary Trust Co | 68,908 | $57.5K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 39,068 | $32.6K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 25,170 | $21.0K | 0.00% | +19,534+346.6% | Added |
| HRT Financial LP | 21,315 | $17.0K | 0.00% | +21,315 | New |
| Northern Trust Corp | 20,136 | $16.8K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 15,426 | $12.9K | 0.00% | +15,426 | New |
| StoneX Group Inc. | 13,668 | $11.7K | 0.00% | +13,668 | New |
Holders of 5% or more of TPST
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Tempest Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Angel Matthew | 13D/A | 37.40%5.53M shares | +1.50 ppfrom 35.90% | Feb 10, 20262 filings | Mar 25, 2026 | SEC |
| Sabby Management, LLC | 13G | 9.90%492.2K shares | New | Jan 21, 20261 filing | Jan 21, 2026 | SEC |